BRIEF—YLB moves ahead with filing for biosimilar Enbrel in Japan

YL Biologics, a joint venture between Japan’s Yoshindo and India’s Lupin says the Japanese medicines regulator has accepted and will review an application for YLB113, the firm’s biosimilar of Enbrel (etanercept).

YLB was established in April 2014 as a joint venture specializing in the development of biosimilars. Manufacturing of YLB113 is subcontracted to a subsidiary of Yoshindo.